Institut Paoli-Calmettes
Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible HLA.
Hematological Diseases
Allogeneic transplant conditioning
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 33 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases |
Actual Study Start Date : | September 2014 |
Estimated Primary Completion Date : | March 2018 |
Estimated Study Completion Date : | March 2020 |
Arm | Intervention/treatment |
---|---|
Other: Busulfan with adapted doses Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine) |
Drug: Allogeneic transplant conditioning |
Ages Eligible for Study: | 55 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Institut Paoli Calmettes
Marseille, France, 13009